AGP Picks
View all

AGP Executive Report

Your go-to archive of top headlines, summarized for quick and easy reading.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

Emerging Infection: WHO is investigating the first reported human case of Shamonda virus, after an immunocompromised older man in eastern France died following severe encephalitis. The virus usually affects livestock, and officials say information on its effects in people is limited. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of serious movement, memory and thinking problems, some persisting after treatment stopped. Cancer Care: ImmunityBio says the first European patients have received Anktiva with BCG for certain bladder cancers. Its conditional EU approval also covers Liechtenstein. Health Cover: Liechtenstein-based Squarelife supports Genki’s updated international health insurance, which now offers cover from one month and expands preventive and dental benefits.

Bladder Cancer Care: The first European patients have received ImmunityBio’s Anktiva with BCG in Germany and Austria. Its conditional approval also covers Liechtenstein and other EEA countries for certain patients with bladder cancer that has not responded to BCG. International Health Cover: Genki has shortened the minimum term for its worldwide health insurance to one month and expanded preventive and dental benefits. The policy is underwritten by Liechtenstein-based Squarelife. Antifungal Treatment: Strong European sales of Cresemba triggered a $37.5 million milestone payment to Swiss company Basilea. The medicine is approved in Liechtenstein and other European markets for serious fungal infections. Medicine Safety: The European Medicines Agency is reviewing Deanxit, a depression and anxiety drug, after reports of serious movement, memory and thinking problems, some persisting after treatment stopped.

International Health Cover: Liechtenstein-based insurer Squarelife is backing an expanded Genki Native plan for expats and digital nomads, now available from one month and with broader preventive and dental cover. Cancer Treatment: First European patients have received ImmunityBio’s bladder cancer therapy Anktiva in Germany and Austria. Its EU approval also covers Liechtenstein. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of serious movement, memory and thinking problems, some persisting after treatment stopped. Local Health Policy: Abortion remains largely illegal in Liechtenstein after Hereditary Prince Alois vetoed a bill that would have allowed first-trimester terminations. Antifungal Treatment: Strong European sales of Cresemba, used for serious fungal infections, triggered a $37.5 million payment to its Swiss developer; the medicine is approved in Liechtenstein.

Cancer Care: ImmunityBio says the first European patients have received Anktiva with BCG for certain bladder cancers in Germany and Austria. The treatment’s conditional European approval also covers Liechtenstein, though local availability was not reported. Insurance: Liechtenstein-based Squarelife underwrites Genki Native, which now offers international health cover from one month, with expanded preventive and dental benefits. Medicine Safety: The European Medicines Agency is reviewing Deanxit, used for depression and anxiety, after reports of serious movement, memory and thinking problems, some persisting after treatment stops. Local Policy: Liechtenstein’s hereditary Prince Alois vetoed a bill to legalize first-trimester abortion, leaving abortion largely illegal. Infection Treatment: Basilea reported strong European sales of antifungal Cresemba, which is approved in Liechtenstein for certain invasive fungal infections.

Cancer Treatment: ImmunityBio says the first European patients have received Anktiva with BCG for certain bladder cancers, in Germany and Austria. The treatment’s EU approval also covers Liechtenstein. Health Insurance: Liechtenstein-based Squarelife underwrites Genki Native, which now offers cover from one month, with expanded preventive and dental benefits and a higher annual limit on its Premium plan. Medicines: Strong European sales of antifungal Cresemba triggered a $37.5 million milestone payment to Basilea; the medicine is approved in Liechtenstein for specified uses. Separately, the European Medicines Agency is reviewing Deanxit after reports of serious movement, memory and thinking problems, some persisting after treatment stops. Reproductive Health: Abortion remains largely illegal in Liechtenstein after Prince Alois vetoed a bill that would have allowed it during the first trimester, saying it did not adequately protect unborn life.

Cancer Care: The first European patients have received ImmunityBio’s bladder-cancer treatment Anktiva with BCG in Germany and Austria. Its conditional EU approval also covers Liechtenstein. Health Insurance: Genki has expanded its international health cover, including preventive and dental care; the policy is underwritten by Liechtenstein-based Squarelife Insurance. Antifungal Treatment: Strong European sales of Cresemba triggered a $37.5 million payment to Basilea. The medicine is approved in Liechtenstein and other European markets for serious fungal infections. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of movement problems and cognitive symptoms, some reportedly continuing after treatment stopped.

International Health Cover: Genki has shortened the minimum term for its worldwide health insurance to one month and expanded preventive and dental cover. The policy is underwritten by Squarelife, a Liechtenstein-based insurer. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of movement problems and cognitive effects, sometimes persisting after treatment ends. Reproductive Health: Hereditary Prince Alois vetoed a bill to legalise first-trimester abortion, leaving the procedure largely illegal in Liechtenstein. Antifungal Treatment: Strong European sales of Cresemba, used for serious fungal infections and approved in Liechtenstein, triggered a US$37.5 million payment to Swiss drugmaker Basilea.

Health Cover: Genki has shortened the minimum term for its worldwide health insurance to one month and expanded preventive and dental benefits. The policy is underwritten by Liechtenstein-based Squarelife Insurance AG. Antifungal Treatment: Strong European sales of Cresemba triggered a $37.5 million milestone payment to Basilea. The medicine is approved for use in Liechtenstein and treats serious fungal infections. Medicine Safety: The European Medicines Agency is reviewing Deanxit, used for depression and anxiety, after reports of potentially persistent movement and cognitive problems. Abortion Law: Liechtenstein’s abortion rules remain largely unchanged after Hereditary Prince Alois vetoed a bill that would have allowed abortion in the first trimester, citing insufficient protection for unborn life.

Medicines: Strong European sales of the antifungal Cresemba triggered a $37.5 million milestone payment to Swiss drugmaker Basilea. The medicine is approved in Liechtenstein for certain invasive fungal infections. Drug Safety: The European Medicines Agency is reviewing depression and anxiety medicine Deanxit after reports of movement problems and memory or thinking difficulties, sometimes continuing after treatment stops. Reproductive Health: Liechtenstein’s Prince Alois has vetoed a bill that would have allowed abortion during the first 12 weeks of pregnancy, leaving the country’s existing restrictions in place.

Medicine Safety: The European Medicines Agency is reviewing Deanxit, a depression and anxiety drug, after reports of movement disorders and memory or thinking problems—some said to persist after treatment ends. The review will assess the risks and whether the combined medicine’s benefits justify them. Reproductive Health: Liechtenstein’s Hereditary Prince Alois vetoed a bill that would have allowed abortion in the first 12 weeks of pregnancy, leaving the country’s existing restrictions in place. Health Funding: Liechtenstein joined Norway and Iceland in agreements making €254 million in EEA and Norway Grants available to Hungary, including €25 million for healthcare.

Medicine Safety: The European Medicines Agency is reviewing Deanxit, a depression and anxiety treatment, after reports of movement disorders and memory or thinking problems. Some symptoms reportedly continued after patients stopped taking it; the review will also assess the benefits of combining its two ingredients. Reproductive Health: Liechtenstein’s abortion laws remain largely unchanged after Hereditary Prince Alois vetoed a bill that would have allowed abortion during the first 12 weeks of pregnancy. Parliament had passed the measure by 13 votes to 12.

Abortion Law: Hereditary Prince Alois vetoed a bill that would have allowed abortion during the first 12 weeks of pregnancy, keeping Liechtenstein’s existing restrictions in place despite parliament’s narrow approval. Antibiotic Resistance: A small, non-random airport study in Sweden and Norway found antibiotics in 3% of checked travellers from the European Economic Area, which includes Liechtenstein. Researchers say the findings warrant closer investigation, but do not establish how common antibiotic carriage is among travellers overall.

Reproductive Health: Hereditary Prince Alois has vetoed a bill narrowly approved by parliament that would have decriminalised abortion during the first 12 weeks. Abortion remains largely illegal, with limited exceptions; the proposed reform also included insurance coverage and fewer restrictions on abortion information. Antibiotic Resistance: A Nordic airport study found antibiotics in 14% of 406 selected passengers’ luggage. Among those checked from the EEA, which includes Liechtenstein, 3% carried them. Researchers caution that the sample was not random and call for further study. Health Funding: Liechtenstein is one of three EEA countries backing a €254 million grant package for Hungary, which includes €25 million for healthcare projects.

Abortion Law: Hereditary Prince Alois has vetoed a bill approved 13–12 by Liechtenstein’s parliament that would have decriminalised abortion during the first 12 weeks of pregnancy. Abortion remains largely illegal, with only narrow exceptions. Antibiotic Resistance: A study at three Nordic airports found antibiotics in 14% of 406 passengers checked; the sample was not random. Among those checked, 3% of travellers from the European Economic Area—including Liechtenstein—carried antibiotics, compared with 27% of travellers from Asia, raising concern about medicines being brought across borders and antimicrobial resistance.

Abortion Access: Hereditary Prince Alois vetoed a bill that would have decriminalised abortion during the first 12 weeks of pregnancy. The reform had narrowly passed parliament; abortion remains largely illegal, with limited exceptions. Animal Health: Shamonda virus has been detected in livestock in Liechtenstein and several other European countries. France has reported the first known human infection; the patient died, but investigators have not established whether the virus contributed. Authorities say no risk to the general public has been identified. Antibiotic Resistance: A small airport study found antibiotics in 3% of checked travellers from the European Economic Area, which includes Liechtenstein. Researchers warned that carrying antibiotics across borders may help spread drug-resistant bacteria.

Reproductive Health: Hereditary Prince Alois vetoed a bill approved by Liechtenstein’s parliament that would have decriminalised abortion during the first 12 weeks of pregnancy. Abortion remains largely illegal, with limited exceptions. Infectious Disease: Shamonda virus has been detected in farm animals in Liechtenstein and other European countries. France has reported the first known human infection; the patient, who was severely immunocompromised, died, but investigators have not established whether the virus contributed. Authorities have identified no risk to the general public. Antibiotic Resistance: A small, non-random airport study found antibiotics in 3% of checked travellers arriving from the European Economic Area. Researchers say carrying antibiotics across borders warrants further attention because some drugs can contribute to resistance.

Infectious Disease: France has confirmed the first human Shamonda virus infection, in a severely immunocompromised patient who later died; investigators have not established whether the virus contributed to the death. The ECDC says this unusual case is no reason for public alarm. Reproductive Health: Hereditary Prince Alois has vetoed a bill that would have decriminalised abortion during the first 12 weeks of pregnancy, blocking reform approved by Liechtenstein’s parliament in a 13–12 vote. Abortion remains illegal except in limited circumstances. Antibiotic Resistance: A small airport study found antibiotics in the luggage of 3% of checked travellers arriving from the European Economic Area, which includes Liechtenstein. Researchers warn that carrying antibiotics across borders may contribute to resistance, but say the findings need closer investigation.

Medical Technology: During Hereditary Prince Alois’s visit to India, the two countries highlighted medical technology and advanced manufacturing as areas for closer cooperation. They also agreed to consider a tax pact to give businesses greater certainty. European Health Funding: Liechtenstein is among the EEA grant donors providing Hungary €25 million for healthcare projects, as part of a wider €254 million funding package. Emerging Virus: France reported the first known human Shamonda virus infection in a severely immunocompromised patient who later died. The cause of death remains unclear; the ECDC says the case warrants attention, not panic. Abortion Access: Prince Alois vetoed a bill that would have decriminalised abortion during the first 12 weeks of pregnancy and allowed insurance coverage, leaving Liechtenstein’s strict restrictions in place.

Reproductive Health: Hereditary Prince Alois has vetoed Liechtenstein’s bill to decriminalise abortion in the first 12 weeks, despite parliament approving it 13–12. Abortion remains largely illegal, with limited exceptions. Emerging Infections: France reported the first known human Shamonda virus infection, in a severely immunocompromised patient who later died. Investigators have not established whether the virus contributed to the death; European health officials say there is no cause for public alarm. Antibiotic Resistance: A small airport study in Sweden and Norway found antibiotics in 14% of checked travellers’ luggage. The sample was not random, but researchers say carrying antibiotics across borders merits closer attention because misuse can fuel drug resistance.

Antibiotic Resistance: Airport checks in Sweden and Norway found antibiotics in 14% of 406 selected travellers. The rate was 3% among travellers from the EEA, including Liechtenstein, and 27% among those from Asia; researchers say the findings need further study. Emerging Infection: France reported the first known human case of Shamonda virus, previously detected in animals. The patient was severely immunocompromised and later died, but investigators have not established whether the virus contributed to the death; authorities say there is no identified risk to the wider public. Reproductive Health: Hereditary Prince Alois vetoed parliament’s narrowly approved bill to allow abortion in the first 12 weeks of pregnancy. The existing ban, with limited exceptions, remains in force.

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Monitor Liechtenstein

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.